


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-1.27%
+3.92%
+1.72%
BMY
Bristol-Myers Squibb
$48.72
Strengths

Earnings are forecast to grow

Investors confidence is positive

Trading below its fair value
Chart
$43.54 (+11.90%)
$48.44 (+0.58%)
$46.84 (+4.01%)
$58.23 (-16.33%)
BMY has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk

BMY overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Earnings decline YoY
Rating
Rating
Momentum
Momentum
Activity
Activity

Investors confidence is positive
Future
Future

Earnings are forecast to grow

Trading below its fair value
![]()
BMY Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
BMY Street Sentiment is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayWhat is BMY current stock price?
What are BMY stock strengths?
What risks are associated with BMY stock?
When is BMY next earnings report?
What is BMY market cap and volume?
What is BMY's current Stock IQ?
Should I buy BMY stock right now?
Is BMY a Strong Buy right now?
What does a 'Strong Buy' rating mean for BMY?
What does a 'Strong Sell' rating mean for BMY?
What factors influence BMY's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-1.27%
+3.92%
+1.72%
BMY
Bristol-Myers Squibb
Current Price
$48.72
Stock Insights
Strengths

Earnings are forecast to grow

Investors confidence is positive

Trading below its fair value

Chart
$43.54 (+11.90%)
$48.44 (+0.58%)
$46.84 (+4.01%)
$58.23 (-16.33%)
BMY Analysts Opinion
BMY Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Earnings decline YoY
Rating
Rating
Momentum
Momentum
Activity
Activity

Investors confidence is positive
Future
Future

Earnings are forecast to grow

Trading below its fair value
![]()
BMY Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
BMY Street Sentiment is extremely bullish and have positive views on the near-term outlook
BMY has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk

Average key support and resistance price levels.
BMY Latest Analysis
BofA Remains Neutral on Bristol-Myers Squibb Company (BMY) Expects Low Single-Digit Growth in the Long Term. Bristol-Myers Squibb Company (NYSE:BMY) is included in our list of the 12 deep value stocks to invest in. On November 3 2025 BofA raised its price target on Bristol-Myers Squibb Company (NYSE:BMY) from $50 to $52 reiterating its Neutral rating. The investment firm revised its 2026 revenue forecast upward 1.5% and EPS forecast upward 1% [….]
Today
Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Surpass Estimates. Bristol Myers (BMY) delivered earnings and revenue surprises of 10.14% and 3.33% respectively for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Thu Oct 30, 2025
Bristol-Myers Q3 Results Beat Street Updates FY25 Outlook Above Market - Update . (RTTNews) - Drug maker Bristol-Myers Squibb Co. (BMY) while reporting higher third-quarter results above the market estimates on Thursday updated fiscal 2025 outlook above the Street.
Thu Oct 30, 2025
Bristol-Myers Squibb Co. Q3 Profit Increases Beats Estimates . (RTTNews) - Bristol-Myers Squibb Co. (BMY) released earnings for its third quarter that Increased from last year and beat the Street estimates.
Thu Oct 30, 2025
Ahead of Bristol Myers (BMY) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics. Besides Wall Streets top-and-bottom-line estimates for Bristol Myers (BMY) review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.
Mon Oct 27, 2025
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It. Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus it is worth knowing the facts that could determine the stocks prospects.
Thu Oct 23, 2025
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for. Bristol Myers (BMY) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Thu Oct 23, 2025
Analyst Says Bristol-Myers Squibb (BMY) Among the Best Deep Value Stocks to Buy. We recently published Top 10 Trending Stocks Everyones Watching in Q4. Bristol-Myers Squibb Company (NYSE:BMY) is one of the trending stocks everyone’.s watching. Morningstars Dave Sekera said in a recent program on Schwab Network that BMY is one of the top deep value stocks today. The analyst mentioned the stocks dividend yield and valuation: Well [….]
Thu Oct 23, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.